Company profile
Vivos Inc.
OTC: RDGL · Healthcare · Medical - Devices
#1071 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
48DFH 39DQ 52GM 67SS 47
v0.1 · 65/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ workforce scale, operating margin
Methodology →Revenue TTM
$77.7k
Rev growth YoY (TTM)
+54.6%
Net income (FY)
-$3.1M
Employees
1
as of 2026-08-20
Market cap
$28.0M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$68.4k$68.4k2025
Net income-$3.1M-$3.1M2025
Operating income-$3.2M-$3.2M2025
Total assets$1.9M$1.9M2025
Liabilities$206.7k$206.7k2025
Equity$1.7M$1.7M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Polymer50%
Freight50%
By geography
Not disclosed.
The read
What is Vivos Inc.’s revenue?
Vivos Inc. booked $68.4k in FY2025 revenue, growing 144% year over year — faster than most Healthcare companies we track, at a -4483.9% net margin.
Peers · Healthcare
eXoZymes, Inc.24DOncotelic Therapeutics, Inc.46DMYND Life Sciences Inc.——Neutra Corp.——Aquarius Surgical Technologies Inc.——Inovio Pharmaceuticals, Inc.37DKey facts
CEOMichael K. Korenko
SectorHealthcare
IndustryMedical - Devices
HeadquartersKennewick, WA
ExchangeOTC: RDGL
Employees1
IPO date1998-09-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.